

Amendments to the Claims:

Please amend the claims as follows, wherein strikeout ~~00~~ indicates deleted terminology and underlining 00 indicates added terminology.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.- 33. (Canceled)

34. (Currently amended) An isolated nucleic acid encoding an antibody ~~that binds to the epitope bound by the 8B8 antibody (ATCC HB-12070), wherein the antibody binds ErbB3 extracellular domain and blocks binding of the 8B8 antibody (ATCC HB-12070), and wherein the antibody reduces heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3.~~ that binds to the epitope bound by the 8B8 antibody (ATCC HB-12070), wherein the antibody binds ErbB3 extracellular domain and blocks binding of the 8B8 antibody (ATCC HB-12070), and wherein the antibody reduces heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3.

35. (Previously presented) The isolated nucleic acid of claim 34 wherein the antibody has the complementarity determining regions of the 8B8 antibody (ATCC HB-12070).

36. (Previously presented) A vector comprising the isolated nucleic acid of claim 34.

37. (Previously presented) A host cell comprising the isolated nucleic acid of claim 34.

38. (Previously presented) A method for making an antibody comprising culturing the host cell of claim 37 so that the nucleic acid is expressed and recovering the antibody from the host cell culture.

39. (Previously presented) The method of claim 38 further comprising conjugating the recovered antibody with a cytotoxic agent or enzyme.